Amneal Pharmaceuticals, Inc. $AMRX Shares Sold by XTX Topco Ltd

XTX Topco Ltd reduced its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 58.8% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 33,918 shares of the company’s stock after selling 48,358 shares during the period. XTX Topco Ltd’s holdings in Amneal Pharmaceuticals were worth $274,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in AMRX. Vanguard Group Inc. lifted its stake in shares of Amneal Pharmaceuticals by 6.2% in the first quarter. Vanguard Group Inc. now owns 15,762,727 shares of the company’s stock valued at $132,092,000 after purchasing an additional 920,758 shares during the period. Charles Schwab Investment Management Inc. increased its holdings in Amneal Pharmaceuticals by 14.8% in the first quarter. Charles Schwab Investment Management Inc. now owns 1,767,594 shares of the company’s stock valued at $14,812,000 after buying an additional 227,660 shares in the last quarter. Deutsche Bank AG lifted its position in shares of Amneal Pharmaceuticals by 128.3% during the 1st quarter. Deutsche Bank AG now owns 305,621 shares of the company’s stock valued at $2,561,000 after acquiring an additional 171,735 shares during the period. Headlands Technologies LLC purchased a new stake in shares of Amneal Pharmaceuticals during the 1st quarter worth approximately $31,000. Finally, Invesco Ltd. grew its holdings in shares of Amneal Pharmaceuticals by 19.2% in the 1st quarter. Invesco Ltd. now owns 2,272,713 shares of the company’s stock worth $19,045,000 after acquiring an additional 365,467 shares during the period. Hedge funds and other institutional investors own 31.82% of the company’s stock.

Wall Street Analysts Forecast Growth

AMRX has been the subject of several research reports. Piper Sandler reaffirmed an “overweight” rating and set a $13.00 price objective (up from $11.00) on shares of Amneal Pharmaceuticals in a report on Friday, October 31st. Barclays assumed coverage on shares of Amneal Pharmaceuticals in a research report on Monday. They issued an “overweight” rating and a $15.00 price objective on the stock. JPMorgan Chase & Co. increased their price objective on shares of Amneal Pharmaceuticals from $12.00 to $14.00 and gave the company an “overweight” rating in a research note on Tuesday, September 16th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Amneal Pharmaceuticals in a report on Wednesday, October 8th. Four research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $13.50.

Insider Activity

In other news, EVP Nikita Shah sold 131,856 shares of the company’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $11.92, for a total transaction of $1,571,723.52. Following the completion of the transaction, the executive vice president owned 146,403 shares of the company’s stock, valued at $1,745,123.76. This represents a 47.39% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Ted C. Nark sold 50,000 shares of the firm’s stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $11.72, for a total transaction of $586,000.00. Following the completion of the sale, the director directly owned 291,029 shares in the company, valued at $3,410,859.88. This represents a 14.66% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 231,856 shares of company stock valued at $2,743,724 in the last 90 days. 17.45% of the stock is owned by company insiders.

Amneal Pharmaceuticals Stock Performance

Shares of AMRX opened at $11.87 on Tuesday. Amneal Pharmaceuticals, Inc. has a fifty-two week low of $6.68 and a fifty-two week high of $12.68. The company has a market capitalization of $3.73 billion, a PE ratio of 593.80 and a beta of 1.36. The stock has a fifty day moving average of $11.08 and a two-hundred day moving average of $9.47.

Amneal Pharmaceuticals (NASDAQ:AMRX) last announced its quarterly earnings data on Thursday, October 30th. The company reported $0.17 EPS for the quarter, beating analysts’ consensus estimates of $0.12 by $0.05. The business had revenue of $784.51 million during the quarter. Amneal Pharmaceuticals had a negative return on equity of 185.60% and a net margin of 0.20%.Amneal Pharmaceuticals has set its FY 2025 guidance at 0.750-0.80 EPS. As a group, equities research analysts forecast that Amneal Pharmaceuticals, Inc. will post 0.53 earnings per share for the current fiscal year.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.